Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.